Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
December 14, 2022 07:00 ET
|
Replay Bio
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology Third product company from Replay expands use of next-generation high payload...
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
November 28, 2022 07:00 ET
|
Replay Bio
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable cell source hypoimmunogenic...
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
November 21, 2022 07:00 ET
|
Replay Bio
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases Second product company using Replay’s next-generation high payload capacity HSV delivery vector developed at...
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
October 31, 2022 07:00 ET
|
Replay Bio
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease First product company using Replay’s high payload capacity HSV vectorUtilizes a next-generation HSV...
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
October 17, 2022 07:00 ET
|
Replay Bio
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts San Diego, California and London, UK, October 17, 2022 – Replay, a genome writing company...
Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA
July 25, 2022 07:00 ET
|
Replay Bio
Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA KKR and OMX Ventures lead $55 million seed funding roundReplay’s genomic medicine toolkit...
Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA
July 25, 2022 02:00 ET
|
Replay Bio
Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA KKR and OMX Ventures lead $55 million seed funding roundReplay’s genomic medicine toolkit...